Advertisement


Tara B. Sanft, MD, on How Diet and Exercise May Affect Completion of Chemotherapy for Breast Cancer

2022 ASCO Annual Meeting

Advertisement

Tara B. Sanft, MD, of Yale University, discusses the results of the LEANer study (Lifestyle, Exercise, and Nutrition Early After Diagnosis) in women with breast cancer. It showed that patients with newly diagnosed disease who were just starting chemotherapy could improve physical activity and diet quality. While both groups had high rates of treatment completion, women in the intervention who exercised at or above the recommended levels did better in terms of treatment completion, with fewer dose reductions and delays (Abstract 12007).

 



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
We know completing chemotherapy as prescribed is important for cancer outcomes. We also know that adopting healthy diet and exercise is important, both for cancer prevention and, in certain cancers, can improve cancer-related survival. The healthy diet and exercise guidelines include eating a predominantly plant-based diet and exercising with moderate intensity exercise at least 150 minutes per week, and performing two strength training sessions per week. Our study, the Lifestyle, Exercise, and Nutrition Study, randomized women who were not meeting these guidelines to a healthy diet and exercise intervention based on the Diabetes Prevention Protocol and adapted using the cancer-related guidelines as well versus usual care, which is referral to our survivorship clinic and dieticians and exercise programs at request by the patient. Our primary outcome was looking at the relative dose intensity, or the actual amount of chemotherapy received compared to that which was prescribed. The intervention group received a year-long intervention of 16 sessions administered by a registered dietician who was certified, specialized in oncology, and also had exercise counseling training. The control group were followed at baseline post-chemotherapy. What we found was that both groups completed chemotherapy at very high rates, with both groups approaching about 93% completion rates. This is higher than what we had found in the literature before. We also found that the number of dose delays and reductions were similar between the two groups. When we looked at the intervention group, in particular, and we looked at if they were meeting the actual recommendations, that is 150 minutes per week and a high consumption of fruits and vegetables, we found that women who were able to meet these guidelines or exceeded them, did have higher completion rates compared to those who didn't quite make those guidelines. So in summary, the women who made the highest number of changes or adhered the best did have better relative dose intensity and fewer dose reductions and delays. But when we took the entire intervention group and compared them to usual care, we did not find a statistically significant difference. In summary, both groups completed their chemotherapy as prescribed most of the time, and the intervention group significantly improved both their diet and physical activity during the course of the intervention. Those who were able to adopt the exercise and diet recommendations the best did have significant improvements in their completion rates and fewer dose reductions and delays compared to those who didn't adopt it as well.

Related Videos

Bladder Cancer
Immunotherapy

Thomas Powles, MD, PhD, and Jonathan E. Rosenberg, MD, on Urothelial Carcinoma: Long-Term Outcomes With Enfortumab Vedotin-ejfv vs Chemotherapy

Thomas Powles, MD, PhD, of Barts Health NHS Trust, Queen Mary University of London, and Jonathan E. Rosenberg, MD, of Memorial Sloan Kettering Cancer Center, discuss the 24-month findings from the phase III EV-301 trial, which suggest that enfortumab vedotin-ejfv continues to show a significant and consistent survival advantage over standard chemotherapy in patients with previously treated advanced urothelial carcinoma (Abstract 4516).

Lymphoma

Andrew D. Zelenetz, MD, PhD, and Michael L. Wang, MD, on Mantle Cell Lymphoma: New Data on Ibrutinib in Combination With Bendamustine/Rituximab and Rituximab Maintenance

Andrew D. Zelenetz, MD, PhD, of Memorial Sloan Kettering Cancer Center, and Michael L. Wang, MD, of The University of Texas MD Anderson Cancer Center, discuss primary results from the phase III SHINE study, which showed that ibrutinib, in combination with bendamustine/rituximab and rituximab maintenance, may set a new benchmark for patients aged 65 or older with mantle cell lymphoma. With a median progression-free survival of 6.7 years, the ibrutinib combination is more beneficial than currently used chemoimmunotherapy (approximately 1.5–3.5 years) (Abstract LBA7502).

Colorectal Cancer

Michael J. Overman, MD, and Jeanne Tie, MBChB, MD, on Colon Cancer: Guiding Adjuvant Chemotherapy With ctDNA

Michael J. Overman, MD, of The University of Texas MD Anderson Cancer Center, and Jeanne Tie, MBChB, MD, of Peter MacCallum Cancer Centre, discuss results from the DYNAMIC trial, in which a circulating tumor DNA (ctDNA)-guided approach reduced the use of adjuvant chemotherapy without compromising recurrence-free survival in patients with stage II colon cancer (Abstract LBA100).

Gynecologic Cancers

Benoit You, MD, PhD, on Ovarian Cancer: Who Benefits From Bevacizumab in the First-Line Setting

Benoit You, MD, PhD, of Lyon University hospital (HCL, France) and GINECO group (France), discusses findings from the GOG-0218 trial of patients with ovarian cancer, which appears to confirm earlier data on the link between poor tumor chemosensitivity and benefit from concurrent plus maintenance bevacizumab. In Dr. You’s validation study, patients who derived the most progression-free and overall survival benefit from bevacizumab were those with high-risk disease (stage IV or incompletely resected stage III) associated with an unfavorable KELIM score (CA-125 kinetic elimination rate constant, calculable online) (Abstract 5553).

Sarcoma

Martin McCabe, PhD, on Ewing Sarcoma: Assessment of Topotecan, Cyclophosphamide, and High-Dose Ifosfamide

Martin McCabe, PhD, of the University of Manchester, discusses a phase III assessment of chemotherapy for patients with recurrent and primary refractory Ewing sarcoma. The trial, called rEECur, is the first study to provide comparative toxicity and survival data for the four most commonly used chemotherapy regimens in this disease. The analysis showed that high-dose ifosfamide is more effective in prolonging survival than topotecan plus cyclophosphamide (Abstract LBA2).

Advertisement

Advertisement




Advertisement